logo

Epizyme, Inc. (EPZM)



Trade EPZM now with
  Date
  Headline
3/14/2018 6:36:52 AM Wedbush Is Raising Epizyme, Inc. (EPZM) FY18 Estimate To -2.02 From -2.15
3/14/2018 6:36:24 AM Wedbush Is Increasing Epizyme, Inc. (EPZM) Q4 18 Estimate To -0.46 From -0.47
3/14/2018 6:36:09 AM Wedbush Is Increasing Epizyme, Inc. (EPZM) Q3 18 Estimate To -0.51 From -0.55
3/14/2018 6:35:56 AM Wedbush Is Increasing Epizyme, Inc. (EPZM) Q2 18 Estimate To -0.53 From -0.57
3/14/2018 6:35:43 AM Wedbush Is Raising Epizyme, Inc. (EPZM) Q1 18 Estimate To -0.52 From -0.56
3/13/2018 7:38:23 AM Epizyme Q4 Net Loss $36.2 Mln Or $0.52/Shr Vs $35.0 Mln Or $0.60/Shr Last Year
11/3/2017 3:18:26 PM Wedbush Is Increasing Epizyme, Inc. (EPZM) FY18 Estimate To -2.15 From -2.18
11/3/2017 3:18:10 PM Wedbush Is Cutting Epizyme, Inc. (EPZM) FY17 Estimate To -2.25 From -2.24
10/27/2017 9:17:52 AM Epizyme Presents Data From Phase1 Trial Of Tazemetostat In Children With Relapsed/Refractory INI1-Negative Solid Tumors
10/25/2017 7:06:08 AM Sierra Oncology Appoints Andrew Allen To Its Board
9/20/2017 6:42:55 AM Jefferies Starts Epizyme, Inc. (EPZM) At Buy With $23 Price Target
9/14/2017 6:31:46 AM Epizyme Reports Pricing Of Public Offering Of 9.18 Mln Shares At $15.25/Shr
9/13/2017 4:03:36 PM Epizyme Announces Proposed Public Offering Of Common Stock
8/15/2017 6:33:35 AM Andrew Singer, EVP, Finance And Administration And CFO Of Epizyme, To Be Leaving At August-end
8/4/2017 6:36:03 AM Epizyme Q2 Net Loss Flat At $28.0 Mln